We are live on ! Find out more
NPSP

NPS PHARMACEUTICALS INC
NPSP

Delisted

NPSP was delisted on the 20th of February, 2015.

200 hedge funds and large institutions have $2.61B invested in NPS PHARMACEUTICALS INC in 2014 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 82 increasing their positions, 69 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 69

3% less call options, than puts

Call options by funds: $73.7M | Put options by funds: $76.2M

7% less funds holding

Funds holding: 215200 (-15)

22% less capital invested

Capital invested by funds: $3.36B → $2.61B (-$750M)

30% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 44

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
200
Holders Change
-15
Holders Change %
-6.98%
% of All Funds
5.8%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.06%
New
31
Increased
82
Reduced
69
Closed
44
Calls
$73.7M
Puts
$76.2M
Net Calls
-$2.52M
Net Calls Change
+$6.98M
Name Holding Trade Value Shares
Change
Change in
Stake
TA
26
Teachers Advisors
New York
$20.2M -$13.9M -485,058 -38%
CPM
27
Chesapeake Partners Management
Maryland
$19.1M +$10.2M +355,000 +93%
Norges Bank
28
Norges Bank
Norway
$18.2M -$20.1M -700,718 -50%
Millennium Management
29
Millennium Management
New York
$18.1M +$19.1M +666,738 +2,193%
VAM
30
Visium Asset Management
New York
$17M -$10.6M -368,246 -36%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$15.1M -$409K -14,233 -2%
Morgan Stanley
32
Morgan Stanley
New York
$13.9M -$268K -9,338 -2%
EA
33
Emerald Advisers
Pennsylvania
$13.7M +$6.31M +219,771 +71%
VOYA Investment Management
34
VOYA Investment Management
Georgia
$13.5M +$13.3M +461,425 +778%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$12.9M +$169K +5,900 +1%
TI
36
Turner Investments
Pennsylvania
$12.2M -$15.5M -538,587 -53%
Bank of America
37
Bank of America
North Carolina
$12.1M -$6.22M -216,411 -32%
HCM
38
Harvey Capital Management
Florida
$11.2M +$5.74K +200 +0%
JP Morgan Chase
39
JP Morgan Chase
New York
$11.1M +$1.31M +45,767 +12%
TCIM
40
TIAA CREF Investment Management
New York
$11.1M -$42.6M -1,484,721 -78%
AAMU
41
Amundi Asset Management US
Massachusetts
$10.9M +$4.74M +165,074 +65%
RFC
42
Russell Frank Company
Washington
$10.8M +$659K +22,943 +6%
Asset Management One
43
Asset Management One
Japan
$10.5M +$8.36M +291,227 +296%
Allianz Asset Management
44
Allianz Asset Management
Germany
$10.2M -$664K -23,106 -6%
Goldman Sachs
45
Goldman Sachs
New York
$10.2M +$2.98M +103,825 +36%
EMFAT
46
Emerald Mutual Fund Advisers Trust
Pennsylvania
$10.2M +$4.88M +169,919 +77%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$9.24M +$1.24M +43,027 +14%
PAM
48
Panagora Asset Management
Massachusetts
$9.1M -$389K -13,557 -4%
Charles Schwab
49
Charles Schwab
California
$9M +$1.4M +48,606 +16%
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$8.9M -$2.69M -93,640 -21%

NPSP Hedge Fund Activity: Q3 2014 in Review

200 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in NPS PHARMACEUTICALS INC (NPSP) for Q3 2014, worth a combined $2.61B — down 22% from $3.36B a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of NPSP and 31 opened new positions — a net loss of 13 holders — while 69 trimmed existing stakes and 82 added.

The largest buyer was OrbiMed, adding an estimated $59.3M. The largest seller was Oak Ridge Investments, exiting entirely with an estimated $93.9M sold.

  • 200 institutional investors held NPS PHARMACEUTICALS INC (NPSP) as of Q3 2014, down from 215 in Q2 2014.
  • Funds reported $2.61B of NPS PHARMACEUTICALS INC stock for Q3 2014, down 22% quarter-over-quarter.
  • 31 funds opened new NPS PHARMACEUTICALS INC positions in Q3 2014 and 44 closed out, a net change of -13 holders.
  • The largest NPS PHARMACEUTICALS INC buyer in Q3 2014 was OrbiMed, an estimated $59.3M added.
  • The largest NPS PHARMACEUTICALS INC seller in Q3 2014 was Oak Ridge Investments, an estimated $93.9M sold.

Based on aggregated 13F filings for Q3 2014.